CN114573732A - Preparation method and application of xylan zinc complex with probiotic effect - Google Patents
Preparation method and application of xylan zinc complex with probiotic effect Download PDFInfo
- Publication number
- CN114573732A CN114573732A CN202210182832.4A CN202210182832A CN114573732A CN 114573732 A CN114573732 A CN 114573732A CN 202210182832 A CN202210182832 A CN 202210182832A CN 114573732 A CN114573732 A CN 114573732A
- Authority
- CN
- China
- Prior art keywords
- xylan
- zinc complex
- reaction
- znso
- zinc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001221 xylan Polymers 0.000 title claims abstract description 67
- 150000004823 xylans Chemical class 0.000 title claims abstract description 64
- 239000011701 zinc Substances 0.000 title claims abstract description 51
- 229910052725 zinc Inorganic materials 0.000 title claims abstract description 47
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000000529 probiotic effect Effects 0.000 title abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 12
- 239000012153 distilled water Substances 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 238000004108 freeze drying Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 230000036541 health Effects 0.000 claims abstract description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims abstract description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims abstract description 3
- 239000011686 zinc sulphate Substances 0.000 claims abstract description 3
- 230000035484 reaction time Effects 0.000 claims description 9
- 235000013406 prebiotics Nutrition 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 244000005709 gut microbiome Species 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 description 12
- 230000012010 growth Effects 0.000 description 9
- 240000006024 Lactobacillus plantarum Species 0.000 description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 description 6
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 5
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- -1 xylan zinc complexes Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000007166 xylan medium Substances 0.000 description 3
- 241000609240 Ambelania acida Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000010905 bagasse Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940091251 zinc supplement Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a preparation method and application of a xylan zinc complex with a probiotic effect, and belongs to the field of health food and medicine research. The xylan zinc complex is prepared by the following method: dissolving 1.0g xylan in 450mL distilled water, stirring for 10min, adding 0.88g ZnSO4·7H2O (dissolved in 20mL of 0.1mol/LIn HCl), adjusting the pH value to 6.0 by using 1mol/L NaOH, reacting for 2h at 60 ℃, dialyzing for 48h with running water, concentrating, and freeze-drying to obtain the xylan zinc complex. The xylan zinc complex prepared by the method and the conditions has the highest zinc content, has the regulation effect on intestinal microflora which is beneficial to health, and has wide application prospect in the research and application of food, health care products and medicines.
Description
Technical Field
The invention relates to a preparation method and application of a xylan zinc complex with a probiotic effect, and belongs to the field of health food and medicine research.
Background
Xylan is the main component of plant hemicellulose, and as the xylan has the active functions of antioxidation, anticoagulation, blood sugar reduction, blood fat reduction, immunoregulation, probiotic effect and the like, previous researches mainly focus on the fields of xylan extraction, structure, biosynthesis and the like, and few mention is made about the influence of xylan and chemical derivatives thereof on intestinal microorganisms.
The complex population and ecological balance of gastrointestinal microorganisms have an important role in maintaining human health. It not only participates in nutrient metabolism, but also is able to defend against invading pathogens. If the intestinal microbial balance is disrupted, chronic intestinal diseases, colorectal cancer, type 2 diabetes, obesity, etc. may result.
By regulating the intake of prebiotics, the gut dysregulated microbiota can be restored to a more predominant equilibrium state of the beneficial bacterial population, thereby exerting a beneficial health effect on humans. Xylan can be degraded by some bacteria in the intestinal tract, degraded into oligosaccharides by the action of enzymes, and then utilized by probiotics. The bagasse extracts xylo-oligosaccharide, and the results of in vitro culture experiments show that compared with fructo-oligosaccharide, the bagasse xylo-oligosaccharide has stronger probiotic effect on the growth of lactobacillus acidophilus, lactobacillus brevis and lactobacillus viridis. The in vitro proliferation experiment of the corncob xylo-oligosaccharide on probiotics shows that the xylo-oligosaccharide can play a good proliferation role on lactobacillus and bacillus subtilis.
Zinc can maintain intestinal function in many ways and is associated with multiple enzymatic activities in the body, and zinc deficiency can be compensated by the intake of organic zinc. Xylan acts as a prebiotic. Can be fermented and utilized in the main field of intestinal bacteria colonization. The ability of microorganisms to utilize polysaccharides is linked to the solubility, molecular weight, etc. properties of the polysaccharides. Therefore, the invention chelates hydroxyl on the xylan skeleton with zinc to form a complex, compares the influence of different preparation conditions on the zinc content of the complex, and determines the xylan zinc complex prepared under the optimal conditions to be used as a zinc supplement.
Disclosure of Invention
The object of the present invention is to provide a process for the preparation of xylan zinc complexes with a maximum zinc content, which xylan zinc complexes have a probiotic action.
A preparation method of xylan zinc complex with probiotic effect specifically comprises the following steps: dissolving xylan in distilled water, stirring to dissolve, adding appropriate amount of ZnSO4·7H2And O, adjusting the pH value to 6.0 by using a sodium hydroxide solution, reacting at a certain temperature, dialyzing for 48 hours by using running water, concentrating, and freeze-drying to obtain the xylan zinc complex. And (3) carrying out a single-factor experiment, investigating the influence of the mass ratio of the reactants, the reaction temperature and the reaction time on the complexing reaction, and finally determining the optimal conditions for preparing the xylan-zinc complex.
The invention achieves the above purpose by the following technical scheme:
(1) dissolving xylan in distilled water, stirring at normal temperature to dissolve, adding ZnSO with different mass ratios4·7H2And O, reacting at 50 ℃ for 1.5h, dialyzing with running water for 48h, concentrating, and freeze-drying to obtain the xylan zinc complex under different reaction mass ratios.
(2) Dissolving xylan in distilled water, stirring and dissolving at normal temperature, and adding ZnSO with the optimal mass ratio determined in the step (1)4·7H2And O, reacting for 1.5h at different temperatures, dialyzing for 48h with running water, concentrating, and freeze-drying to obtain xylan zinc complex at different reaction temperatures.
(3) Dissolving xylan in distilled water, stirring and dissolving at normal temperature, and adding ZnSO with the optimal mass ratio determined in the step (1)4·7H2O, reacting at the optimal reaction temperature determined by the step (2) for different times respectively,dialyzing with running water for 48h, concentrating, and freeze-drying to obtain xylan zinc complex under different reaction times.
Drawings
FIG. 1 shows the effect of the reaction mass ratio on the zinc content of the xylan zinc complex
FIG. 2 shows the effect of the temperature for carrying out the reaction on the zinc content of the xylan zinc complex
FIG. 3 is a graph showing the effect of the reaction time on the zinc content of xylan zinc complex
FIG. 4 shows the effect of the xylan and xylan zinc complex on the growth curve of Lactobacillus delbrueckii
FIG. 5 shows the effect of the xylan and xylan zinc complex on the growth curve of Lactobacillus plantarum
Detailed Description
The technical solution of the present invention is further illustrated by the following examples.
Determination of the preparation of xylan complexes under optimal conditions:
(1) dissolving 0.5g xylan in 250mL distilled water according to single variable principle, stirring and dissolving at normal temperature for 10min, controlling the reaction temperature at 50 ℃ and the reaction time at 1.5h, and respectively adding ZnSO with different mass ratios (Zn: XY is 0.1, 0.15, 0.2, 0.25 and 0.3)4·7H2O, determining the optimal Zn to XY mass ratio to be 0.2; then 0.44g of ZnSO was added in a controlled manner4·7H2O and the reaction time is 1.5h, the reaction is carried out at different temperatures (40, 50, 60, 70 and 80 ℃), and the optimal reaction temperature is determined to be 60 ℃; finally, 0.44g of ZnSO was added in a controlled manner4·7H2O and the reaction temperature is 60 ℃, the reaction is carried out for different times (1, 2, 3, 4 and 5 hours), and the optimal reaction time is determined to be 2 hours.
(2) According to the optimal reaction conditions determined in (1), 1.0g of xylan is dissolved in 450mL of distilled water, stirred and dissolved for 10min at normal temperature, and 0.88g of ZnSO is added4·7H2O (dissolved in 20mL of 0.1 mol/LHCl), adjusting the pH value to 6.0 by using 1mol/L NaOH, reacting for 2h at 60 ℃, dialyzing for 48h with running water, concentrating, and freeze-drying to obtain the xylan zinc complex.
In vitro culture of probiotics:
mu.L of the glycerol-preserved strain was inoculated into the corresponding sterilized 100mL of MRS medium and cultured in a constant temperature incubator at 36 ℃ for 24 hours. And then inoculating the activated strain to an MRS agar culture medium by using a plate streaking method, culturing at 36 ℃ until an obvious colony is formed, selecting a single colony with better growth vigor, inoculating to an MRS liquid culture medium, and culturing at 36 ℃ for 24 hours for growth curve determination.
Activated lactobacillus delbrueckii and lactobacillus plantarum are respectively inoculated into 4mL of carbon source culture medium of xylan and xylan zinc complex with the inoculation amount of 1% (40 mu L), the culture is carried out in a constant temperature incubator at 36 ℃, 3 times are repeated in each group, and each carbon source culture medium is inoculated with sterile water to serve as a blank control. 100. mu.L of the medium was taken out from the clean bench at 2h intervals within 24h after inoculation, and the OD (600nm) value was measured. The OD was then measured once more at 30h and 36h, respectively. And drawing a probiotic growth curve by taking the culture time as an abscissa and the OD value as an ordinate.
(1) Lactobacillus delbrueckii
The influence of xylan and zinc xylan complex on the growth curve of Lactobacillus delbrueckii was studied, and the results are shown in FIG. 4, and the xylan medium was similar to the zinc xylan complex medium in terms of the time range and maximum growth in the logarithmic growth phase. After 22h, the OD values of the xylan culture medium and the xylan zinc complex culture medium are not changed greatly any more, tend to be stable and are in a parallel state, and the OD value of the xylan zinc complex culture medium is slightly higher than that of the xylan culture medium, so that the result shows that the value-added effect of the xylan zinc complex on lactobacillus delbrueckii is stronger than that of xylan, and the certain probiotic effect of the xylan zinc complex is stronger than that of xylan.
(2) Lactobacillus plantarum
The influence of xylan and xylan zinc complex on the growth curve of lactobacillus plantarum was studied, and the results are shown in fig. 5, wherein lactobacillus plantarum grows in xylan medium at about 6-10h log phase, and xylan zinc complex medium is about 2h later than xylan medium. 12h to 20h, compared with the xylan culture medium, the OD value of the xylan zinc complex culture medium is higher. After the logarithmic growth phase, the OD value of the xylan zinc complex culture medium tends to be in a more stable state, and the change amplitude is smaller than that of the xylan culture medium, so that both xylan and xylan zinc complex have a certain probiotic effect on lactobacillus plantarum.
Claims (6)
1. A preparation method of a xylan zinc complex is characterized by comprising the following specific steps:
(1) dissolving 0.5g xylan in 250mL distilled water according to single variable principle, stirring and dissolving at normal temperature for 10min, controlling the reaction temperature at 50 ℃ and the reaction time at 1.5h, and respectively adding ZnSO with different mass ratios (Zn: XY is 0.1, 0.15, 0.2, 0.25 and 0.3)4·7H2O, determining the optimal Zn to XY mass ratio to be 0.2;
(2) then, 0.44g of ZnSO was added4·7H2O and the reaction time is 1.5h, the reaction is carried out at different temperatures (40, 50, 60, 70 and 80 ℃), and the optimal reaction temperature is determined to be 60 ℃;
(3) finally, 0.44g of ZnSO is added in a controlled manner4·7H2O and the reaction temperature is 60 ℃, the reaction is carried out for different times (1, 2, 3, 4 and 5 hours), and the optimal reaction time is determined to be 2 hours.
2. The method for preparing xylan zinc complex according to claim 1 wherein the optimal reaction conditions are integrated: dissolving 1.0g xylan in 450mL distilled water, stirring at normal temperature for 10min, adding 0.88g ZnSO4·7H2O (dissolved in 20mL of 0.1mol/L HCl), adjusting the pH value to 6.0 by using 1mol/L NaOH, reacting at 60 ℃ for 2h, dialyzing with running water for 48h, concentrating, and freeze-drying to obtain the xylan zinc complex.
3. Use of a xylan zinc complex according to claim 2 for the preparation of a medicament or nutraceutical for prebiotic effects, maintaining the health of the intestine.
4. Use according to claim 3, characterized in that: a xylan zinc complex prepared by the process of claim 2.
5. Use according to claim 3, characterized in that: the dosage form of the medicine or the health care product is tablets, granules, hard capsules, soft capsules, oral liquid, powder, mixture, pills or dropping pills.
6. A pharmaceutical composition characterized by: comprising the xylan zinc complex according to claim 2 as an active ingredient together with a pharmaceutically acceptable carrier or adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210182832.4A CN114573732A (en) | 2022-02-27 | 2022-02-27 | Preparation method and application of xylan zinc complex with probiotic effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210182832.4A CN114573732A (en) | 2022-02-27 | 2022-02-27 | Preparation method and application of xylan zinc complex with probiotic effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114573732A true CN114573732A (en) | 2022-06-03 |
Family
ID=81771836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210182832.4A Pending CN114573732A (en) | 2022-02-27 | 2022-02-27 | Preparation method and application of xylan zinc complex with probiotic effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114573732A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116874643A (en) * | 2023-05-27 | 2023-10-13 | 桂林理工大学 | Xylan calcium complex and application thereof in antioxidant products |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170101621A1 (en) * | 2007-07-26 | 2017-04-13 | Bioman S.R.L. | Zinc-enriched biomass, method for the preparation thereof and pro-biotic, cosmetic, dietary and nutraceutic products comprising the same |
| WO2017068424A1 (en) * | 2015-10-22 | 2017-04-27 | THOREL JEAN-NOëL | Composition based on dihydromyricetin and a zinc salt for the treatment of acne and oily skin |
-
2022
- 2022-02-27 CN CN202210182832.4A patent/CN114573732A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170101621A1 (en) * | 2007-07-26 | 2017-04-13 | Bioman S.R.L. | Zinc-enriched biomass, method for the preparation thereof and pro-biotic, cosmetic, dietary and nutraceutic products comprising the same |
| WO2017068424A1 (en) * | 2015-10-22 | 2017-04-27 | THOREL JEAN-NOëL | Composition based on dihydromyricetin and a zinc salt for the treatment of acne and oily skin |
Non-Patent Citations (2)
| Title |
|---|
| 刘丽娅等: ""小麦麸皮***木聚糖体外益生活性研究"" * |
| 马茂涛: ""牡蛎多糖螯合锌的制备螯合及其对脂多糖刺激断奶仔猪小肠健康的影响"" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116874643A (en) * | 2023-05-27 | 2023-10-13 | 桂林理工大学 | Xylan calcium complex and application thereof in antioxidant products |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaur et al. | Bacterial exopolysaccharides as emerging bioactive macromolecules: from fundamentals to applications | |
| Kilian et al. | The effects of the novel bifidogenic trisaccharide, neokestose, on the human colonic microbiota | |
| CN101366734A (en) | Synbiotics medicament composition | |
| CN113122467B (en) | Lactobacillus paracasei and composition thereof | |
| CN106834196A (en) | Lactobacillus plantarum CH126 and its application in function of polysaccharide food is prepared | |
| CN103421715B (en) | Lactobacillus rhamnosus and application thereof | |
| CN114854643A (en) | Culture medium for promoting lactobacillus and bifidobacterium to co-proliferate and application thereof | |
| CN114642686B (en) | Composite probiotics and its functions of delaying senility and resisting oxidation | |
| CN107164295A (en) | A kind of selenium-enriched microbe its preparation method and application | |
| CN112274577B (en) | Use of a composition comprising a fermentation of a Musa species and a probiotic composition | |
| CN114573732A (en) | Preparation method and application of xylan zinc complex with probiotic effect | |
| CN115120646A (en) | Probiotic composition for balancing intestinal flora and preparation method and application thereof | |
| CN112391318B (en) | Preparation method of bifidobacterium longum and selenium-enriched microorganism and preparation method of freeze-dried preparation thereof | |
| CN111920048B (en) | Capsule containing rose fermentation liquor and preparation method thereof | |
| CN113773978B (en) | Bifidobacterium adolescentis and application thereof | |
| CN101880703B (en) | Method for fermenting daptomycin by adding caprate | |
| CN110680837A (en) | Lactobacillus plantarum and application thereof in improving intestinal IL-17F expression level | |
| CN114456969A (en) | Probiotic preparation for losing weight and reducing blood sugar as well as preparation method and application thereof | |
| CN116195740A (en) | Prebiotics and probiotic compositions for improving the resistance of organisms to staphylococcus aureus infections | |
| KR101444216B1 (en) | Probiotic Lactobacillus brevis JSB22 Having Extracellular Polysaccharide Producing Actibity | |
| CN112322531A (en) | Production method and application of high-activity lactobacillus acidophilus freeze-dried powder | |
| CN114806920B (en) | Culture medium of bifidobacterium and culture method and application thereof | |
| CN114532540B (en) | Maltopentaosyl trehalose and application of microsphere thereof in regulating intestinal flora | |
| CN115386518B (en) | Lactobacillus rhamnosus strain with D-psicose as carbon source, and derivative product and application thereof | |
| CN103402377A (en) | Indirect substrates for microorganisms metabolizing 1,2-propanediol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |